These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 9656099)

  • 61. [Prostate-specific antigen (PSA)].
    Huland H
    Urologe A; 1995 Jul; 34(4):273-4. PubMed ID: 7545840
    [No Abstract]   [Full Text] [Related]  

  • 62. Prostate carcinoma with peripheral metastases after prostatectomy and low levels of serum prostate specific antigen.
    Seven B; Varoglu E; Cayir K; Sahin A; Kantarci M
    Hell J Nucl Med; 2008; 11(1):53-4. PubMed ID: 18392233
    [No Abstract]   [Full Text] [Related]  

  • 63. [Clinical evaluation on serum osteocalcin in advanced prostate cancer patients].
    Abe H; Nakagami YJ; Ito H; Ikeda K; Oka F; Niwa N
    Hinyokika Kiyo; 1991 Aug; 37(8):877-80. PubMed ID: 1720275
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Prostate specific antigen: a role of PSA in the diagnosis of prostate cancer].
    Nutahara K; Higashihara E
    Nihon Rinsho; 2000 Jul; 58 Suppl():95-8. PubMed ID: 11022692
    [No Abstract]   [Full Text] [Related]  

  • 65. Re: Biopsy after external beam radiation therapy for adenocarcinoma of the prostate: correlation with original histological grade and current prostate specific antigen levels.
    Kabalin JN
    J Urol; 1992 Nov; 148(5):1565-6. PubMed ID: 1279220
    [No Abstract]   [Full Text] [Related]  

  • 66. [Prostate-specific antigen (PSA) is a valuable marker--if correctly used].
    Ekman P
    Lakartidningen; 1991 Jun; 88(24):2207-8. PubMed ID: 1711643
    [No Abstract]   [Full Text] [Related]  

  • 67. [Prostate-specific antigen (PSA) and PSA-ACT].
    Kuriyama M; Uno H
    Nihon Rinsho; 1999 Dec; 57 Suppl():520-2. PubMed ID: 10778179
    [No Abstract]   [Full Text] [Related]  

  • 68. Bone metastases from prostate cancer without elevated prostate-specific antigen levels: diagnosis by anti-PSA immunostaining.
    Berthelot JM; Gouin F; Denis M; Nomballais MF; Maugars Y; Blaive-Cervi S; Prost A
    Rev Rhum Engl Ed; 1995 Jan; 62(1):54-5. PubMed ID: 7540487
    [No Abstract]   [Full Text] [Related]  

  • 69. [Prostate-specific antigen: an evaluation 15 years after its discovery].
    Janssen T; Schulman C
    Prog Urol; 1994 Apr; 4(2):171-80. PubMed ID: 7515305
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Clinical use of posttherapy prostate-specific antigen changes in advanced prostate cancer.
    Kelly WK; Slovin S; Scher HI
    Semin Oncol; 1996 Dec; 23(6 Suppl 14):8-14. PubMed ID: 8996578
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [PSA density, PSA velocity and PSA doubling time].
    Kurokawa K
    Nihon Rinsho; 2000 Jul; 58 Suppl():103-7. PubMed ID: 11022694
    [No Abstract]   [Full Text] [Related]  

  • 72. [Management of prostate cancer in Senegal: what is being done?].
    Niang L; Ndoye M; Ouattara A; Jalloh M; Labou M; Thiam I; Kouka SC; Diaw JJ; Gueye SM
    Prog Urol; 2013 Jan; 23(1):36-41. PubMed ID: 23287482
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Prostate cancer].
    Hefermehl L; Elke B; Sulser T
    Praxis (Bern 1994); 2010 Feb; 99(3):149-56, 158; quiz 157. PubMed ID: 20127633
    [No Abstract]   [Full Text] [Related]  

  • 74. [Incidental prostatic adenocarcinoma in the ere of the PSA].
    Picurelli Oltra L; Sendra Torres A; Fernández Rodríguez A; Ortega Villar F; Baixauli Martínez J; Tramoyeres Celma A
    Actas Urol Esp; 1997 Apr; 21(4):354-6. PubMed ID: 9265406
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Value of prostate-specific antigen as a tumor marker.
    Wirth M; Manseck A; Heimbach D
    Eur Urol; 1993; 24 Suppl 2():6-12. PubMed ID: 7505232
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A medical reveals a slightly raised PSA.
    Spira M; Kirby M; Williams G
    Practitioner; 1997 Jun; 241(1575):303, 307-10, 313 passim. PubMed ID: 9230511
    [No Abstract]   [Full Text] [Related]  

  • 77. False-positive serum prostate-specific antigen values in a patient with non-Hodgkin lymphoma of the kidney.
    Djavan B; Keffer JH; Molberg K; Roehrborn CG
    Urology; 1995 May; 45(5):875-8. PubMed ID: 7538247
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Recurrent prostate cancer despite undetectable prostate specific antigen.
    Takayama TK; Krieger JN; True LD; Lange PH
    J Urol; 1992 Nov; 148(5):1541-2. PubMed ID: 1279216
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A quantitative model for the dynamics of serum prostate-specific antigen as a marker for cancerous growth: an explanation for a medical anomaly.
    Swanson KR; True LD; Lin DW; Buhler KR; Vessella R; Murray JD
    Am J Pathol; 2001 Jun; 158(6):2195-9. PubMed ID: 11395397
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The current role of circulating tumor cells in the diagnosis and management of bone metastases in advanced prostate cancer.
    Saad F; Pantel K
    Future Oncol; 2012 Mar; 8(3):321-31. PubMed ID: 22409467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.